TY  - JOUR
AU  - Esteban, Rafael
AU  - Pineda, Juan A
AU  - Calleja, Jose Luis
AU  - Casado, Marta
AU  - Rodriguez, Manuel
AU  - Turnes, Juan
AU  - Morano Amado, Luis Enrique
AU  - Morillas, Rosa Maria
AU  - Forns, Xavier
AU  - Pascasio Acevedo, Juan Manuel
AU  - Andrade, Raul J
AU  - Rivero, Antonio
AU  - Carrion, Jose Antonio
AU  - Lens, Sabela
AU  - Riveiro-Barciela, Mar
AU  - McNabb, Brian
AU  - Zhang, Gulan
AU  - Camus, Gregory
AU  - Stamm, Luisa M
AU  - Brainard, Diana M
AU  - Subramanian, G Mani
AU  - Buti, Maria
PY  - 2018
DO  - 10.1053/j.gastro.2018.06.042
UR  - http://hdl.handle.net/10668/12659
T2  - Gastroenterology
AB  - In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and...
LA  - en
PB  - Elsevier
KW  - Direct-acting antiviral agent
KW  - Drug resistance
KW  - Outcome
KW  - Antiviral agents
KW  - Carbamates
KW  - Drug combinations
KW  - Drug resistance, bacterial
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - Hepatitis C
KW  - Heterocyclic compounds, 4 or more rings
KW  - Humans
KW  - Liver cirrhosis
KW  - Male
KW  - Middle aged
KW  - RNA, viral
KW  - Ribavirin
KW  - Sofosbuvir
KW  - Spain
KW  - Sustained virologic response
KW  - Time factors
KW  - Treatment outcome
KW  - Viral load
TI  - Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
TY  - research article
VL  - 155
ER  -